David Thomas

Dr. David Y. Thomas is CEO of Traffick Therapeutiques/therapeutiques Inc, of Montreal, Canada, a company specializing in the development of therapies for protein trafficking diseases such as cystic fibrosis. The company collaborates with pharmaceutical and medicinal chemistry companies and has project-specific investments. Dr Thomas obtained his Ph.D., at University College London and has made original contributions in several areas of genetics and biochemistry. Through discovery of the components of the 'Calnexin cycle' he established the mechanism of folding and quality control of secreted proteins.